A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

Abstract

OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia. Our aim in this study is comparison of second-generation depot antipsychotics and second-generation oral antipsychotics used in the treatment of patients with schizophrenia in terms of metabolic syndrome criteria. METHODS: We included 39 patients treated with second-generation depot antipsychotics and 124 patients treated with second-generation oral antipsychotics, who were diagnosed with schizophrenia. Positive and Negative Syndrome Scale was applied to all the patients and blood pressure, weight, height, body mass index, waist circumference, fasting blood glucose, triglyceride level, and high-density lipoprotein (HDL) levels were recorded. RESULTS: In terms of metabolic syndrome criteria, the waist circumference and triglyceride levels of the patients treated with the second-generation depot antipsychotics were lower than those of the patients treated with second-generation oral antipsychotics, and the HDL levels were statistically significantly higher. CONCLUSION: In this study, second-generation depot antipsychotics used in the treatment of schizophrenia patients were found to be associated with more positive results in terms of metabolic syndrome criteria than oral antipsychotic drug forms. ARTICLE HISTORY

Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players

“…Antipsychotics form the mainstay of treatment for patients with schizophrenia, but many are associated with weight gain, lipid disturbance, and glucose dysregulation, thereby contributing to the development of metabolic syndrome (6). Recent comparisons and even rankings of different antipsychotics published on the basis of their metabolic side-effects, represent examples of the growing concern about this circumstance (6)(7)(8). According to this issue, it is well known that clozapine and olanzapine are associated with the highest metabolic impact (9).…”

Influence of the use of atypical antipsychotics in metabolic syndrome

“…This study, in which depot formulae were compared to habitual drugs taken orally, showed that the abdominal circumference and triglycerides were lower when using depot preparations than when taking daily oral doses. HDL cholesterol was also seen to increase more in patients using depot preparations 18 .…”

“…En este estudio, donde se comparaban fórmulas Depot frente a los tratamientos habituales en forma oral, se observó que, con el uso de los preparados Depot, el perímetro abdominal y los triglicéridos fueron más bajos que en los que usaron formas orales diarias. También, de la misma manera, el colesterol HDL aumentó más en los que usaban preparados Depot 18 .…”